Pharmaceuticals News 5 December 2025

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached

8 December 2025

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something

8 December 2025

Artificial Intelligence · Biotechnology · Clinical Trials · Pharmaceuticals · Stock Analysis

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. (NYSE: MRK) enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a

8 December 2025

Company News · Financial Analysis · Investing · NYSE:MRK · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

As Wall Street heads into Monday’s session, Eli Lilly and Company (NYSE: LLY) sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price

7 December 2025

Financial News · Investing · Market Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX

7 December 2025

Biotechnology · Drug Development · Investment Analysis · NASDAQ:VRTX · Pharmaceuticals · Stock Market

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt

7 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable

7 December 2025

Financial News · Healthcare Industry · Investment Analysis · NYSE:NVO · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly and Company (NYSE: LLY) heads into the final weeks of 2025 as one of the most closely watched stocks on Wall Street – and not just in healthcare. After briefly crossing the $1 trillion market-cap mark in November

6 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Published: December 6, 2025 – For information only, not investment advice. Johnson & Johnson stock (NYSE: JNJ) is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings

6 December 2025

Cancer Research · Investment Analysis · Legal News · NYSE:JNJ · Pharmaceuticals · Stock Market

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock (NASDAQ: GILD) is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At

6 December 2025

Dividends · Financial News · Investment Analysis · NASDAQ:GILD · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Updated: December 5, 2025 Eli Lilly and Company (NYSE: LLY) remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on

5 December 2025

Company Analysis · Financial News · Investing · Pharmaceuticals · Stock Market

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK share price today, latest news, dividend, buyback activity and stock forecast as of 5 December 2025. GSK Share Price: Trading Near Multi‑Year Highs After a Strong 2025 GSK plc (LON:GSK; NYSE:GSK) is heading into year‑end 2025 on the front

5 December 2025

Corporate News · Investment Strategies · Market Analysis · NYSE:GSK · Pharmaceuticals · Stocks

Pharmaceuticals News 5 December 2025 - 8 December 2025